Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renata Colombo Bonadio

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Breast Cancer Research and Treatment|February 3, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real studyRenata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Clinics (Sao Paulo, Brazil)|July 14, 2026
Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiationCamila M Venchiarutti Moniz, Renata Colombo Bonadio, Felippe Lazar, et al.
Breast (Edinburgh, Scotland)|August 6, 2025
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 studyLeandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, et al.
Breast (Edinburgh, Scotland)|April 16, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, et al.
JCO Oncology Practice|March 6, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo, et al.
Breast Cancer Research and Treatment|March 18, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Renata Colombo Bonadio, Agustina Ipiña, et al.
NPJ Breast Cancer|March 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, et al.
NPJ Breast Cancer|June 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohortMonique Celeste Tavares, Flávia C Balint, Romualdo Barroso-Sousa, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Breast Cancer Research and Treatment|February 3, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real studyRenata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Clinics (Sao Paulo, Brazil)|July 14, 2026
Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiationCamila M Venchiarutti Moniz, Renata Colombo Bonadio, Felippe Lazar, et al.
Breast (Edinburgh, Scotland)|August 6, 2025
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 studyLeandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, et al.
Breast (Edinburgh, Scotland)|April 16, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, et al.
JCO Oncology Practice|March 6, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo, et al.
Breast Cancer Research and Treatment|March 18, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Renata Colombo Bonadio, Agustina Ipiña, et al.
NPJ Breast Cancer|March 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, et al.
NPJ Breast Cancer|June 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohortMonique Celeste Tavares, Flávia C Balint, Romualdo Barroso-Sousa, et al.
Pageof 5